Endothelial arginase II: a novel target for the treatment of atherosclerosis

Circ Res. 2008 Apr 25;102(8):923-32. doi: 10.1161/CIRCRESAHA.107.169573. Epub 2008 Feb 28.

Abstract

Oxidized low-density lipoproteins increase arginase activity and reciprocally decrease endothelial NO in human aortic endothelial cells. Here, we demonstrate that vascular endothelial arginase activity is increased in atherogenic-prone apolipoprotein E-null (ApoE(-/-)) and wild-type mice fed a high cholesterol diet. In ApoE(-/-) mice, selective arginase II inhibition or deletion of the arginase II gene (Arg II(-/-) mice) prevents high-cholesterol diet-dependent decreases in vascular NO production, decreases endothelial reactive oxygen species production, restores endothelial function, and prevents oxidized low-density lipoprotein-dependent increases in vascular stiffness. Furthermore, arginase inhibition significantly decreases plaque burden. These data indicate that arginase II plays a critical role in the pathophysiology of cholesterol-mediated endothelial dysfunction and represents a novel target for therapy in atherosclerosis.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Apolipoproteins E / deficiency
  • Arginase / antagonists & inhibitors
  • Arginase / genetics
  • Arginase / physiology*
  • Atherosclerosis / etiology*
  • Atherosclerosis / pathology
  • Cholesterol / administration & dosage
  • Endothelial Cells / pathology
  • Endothelium, Vascular / pathology
  • Endothelium, Vascular / physiopathology
  • Mice
  • Mice, Knockout
  • Nitric Oxide / biosynthesis
  • Nitric Oxide Synthase Type III
  • Up-Regulation
  • Vascular Resistance

Substances

  • Apolipoproteins E
  • Nitric Oxide
  • Cholesterol
  • Nitric Oxide Synthase Type III
  • Arg2 protein, mouse
  • Arginase